^
    1d
    Immunohistochemical Evaluation of PD-L1 Expression in Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer. (PubMed, Anticancer Agents Med Chem)
    PD-L1 expression may be associated with tumor grade in early-stage endometrioid endometrial cancer. However, its clinical significance remains unclear. These findings may be relevant in the context of fertility- preserving management and require further investigation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    2d
    Novel Pattern of Nuclear Staining With ROS1 Immunohistochemistry: A Case Report. (PubMed, Case Rep Pulmonol)
    Immunostaining for ALK was negative, and there was no expression of PD-L1 22C3 IHC. This case report highlights an unexpected ROS1 IHC staining associated with a rare ROS1 gene rearrangement.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ROS1 rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    6d
    RADIAN: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2027 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    7d
    SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=264, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P1/2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Enshuxing (enlonstobart)
    8d
    Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)
    12d
    Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, Everest Medicines (Beijing) Co., Ltd.
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Idafang (ivonescimab)
    14d
    TRIFOUR: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=117, Completed, Cantargia AB | Active, not recruiting --> Completed
    Trial completion • BRCA Companion diagnostic • PARP Companion diagnostic
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
    |
    PD-L1 IHC 22C3 pharmDx • Prosigna® Breast Risk of Recurrence (ROR) Test
    |
    carboplatin • gemcitabine • nadunolimab (CAN04)
    16d
    Comprehensive characterization of non-small cell lung cancer of different PD-L1 expression classes: a study of 1,038 Chinese patients. (PubMed, J Thorac Dis)
    This study enriches the current volume of evidence on histopathologic, genetic, immunologic correlates of PD-L1 expression and, to our knowledge, is the first comprehensive analysis of arm-level alterations. Further studies are warranted to validate these finding and to determine their associations with clinical outcomes.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression • BRAF V600E • KRAS mutation • PD-L1 overexpression • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • MET exon 14 mutation • ALK fusion • ALK mutation • ROS1 fusion • MET mutation • KRAS G12 • EGFR positive • HER-2 exon 20 mutation
    |
    PD-L1 IHC 22C3 pharmDx
    16d
    Visualization of Scattered Tumor Regression Following Neoadjuvant Chemoimmunotherapy With a Novel Intraoperative PET/CT Scanner. (PubMed, Head Neck)
    Pathologic response to neoadjuvant chemoimmunotherapy in HNSCC can manifest as a multifocal regression pattern. Intraoperative real-time approaches to assessing treatment response warrant further investigation.
    Journal
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    18d
    p53 expression and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS ≥ 50%), defined with 22C3 antibody. (PubMed, Discov Oncol)
    The present study is the first to reveal that distinct subtypes of PD-L1-high LUAD can be identified on the basis of p53 protein expression and the NLR. p53 expression and the NLR can recognize a subtype with brisk immune cell cytotoxicity that might potentially respond better to PD-1 inhibitors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    TP53 mutation • EGFR mutation • PD-L1 overexpression • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    19d
    Clinicopathological characteristics and prognostic analysis of synchronous endometrioid endometrial and ovarian carcinomas: a retrospective cohort study. (PubMed, BMC Womens Health)
    These findings support the prognostic significance of poor tumor differentiation, > 50% myometrial invasion, LVSI, lymph node metastasis, and 2023 FIGO staging system in SEEOCs. The high rates of dMMR, HER2, and PD-L1 positivity in SEEOCs suggest potential for targeted therapies in future therapeutic strategies.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53)
    |
    PD-L1 expression • TP53 mutation • MSI-H/dMMR • HER-2 expression • PD-L1 expression + HER-2 overexpression
    |
    PD-L1 IHC 22C3 pharmDx
    22d
    Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% (clinicaltrials.gov)
    P2, N=60, Recruiting, Tang-Du Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK fusion • ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Hetronifly (serplulimab)